Vincent Mutel, CEO

PhD, Serial entrepreneur, expert in CNS pharmacology and drug development

Vincent Mutel is currently CEO, co-founder and member of the BoD of Inflamalps, a biopharmaceutical company developing novel medicines, with a focus on chronic inflammatory diseases of the eye. Vincent was previously co-founder, CEO and vice chairman of the board of Addex Pharmaceuticals Ltd, a well-established public Swiss biotech, and prior was Research Area Head in the CNS division at the Swiss pharmaceutical company F. Hoffmann-La Roche Ltd where he worked for 13 years. Vincent is a biochemist and pharmacologist by training and has initiated and successfully driven several R&D projects bringing molecules from discovery to advanced clinical trial. In his role at Addex Pharmaceuticals Ltd he led the growth of the organization to up to 140 staff, completed three rounds of venture financing, an IPO and a PIPE, totaling CHF263 million, and signed three major drug development partnerships, two with Merck & Co., Inc. and one with Ortho-McNeil-Janssen Pharmaceuticals Inc., a Johnson & Johnson company, representing CHF43 million in realized revenues.

Selena Bodennec, CSO and Co-founder

PhD, Expert in molecular biology, pharmacology and cell biology, with particular experience in lipid biochemistry

Skilled in molecular and cell biology, with particular experience in lipid biochemistry. Selena investigated lipid metabolism of marine organisms by establishing connection between the environmental changes and phospholipid metabolism of marine organisms. This work contributed to the discovery of the lipidic vectors. Formerly active in research trial with lipid drugs. Weizmann Institute of Science graduate.

Laurent Bezin, Co-founder

PhD, Expert in epileptology, neuroinflammation and molecular biology

Expert in molecular and cell neurobiology, neuroinflammation, behavior and epilepsy. Deputy Director of the Lyon Neuroscience Research Center and the European Epilepsy Institute. Co-head of the TIGER team. VP of two associations, aimed at improving the quality of life of people with epilepsy or pervasive developmental disorders through meditation and a multi-sensory enrichment program.

Amor Belmeguenai, Co-founder

PhD, Expert in neurophysiology, electrophysiology, cellular/molecular mechanisms of learning and memory

Over the last decade, Amor has developed a solid experience in the development and evaluation of innovative therapeutic strategies for cognitive impairment in many neurological disorders, including epilepsy. Amor’s efforts are particularly devoted to the combination paradigm of pharmacological and non-pharmacological approaches to better prevent or treat epilepsy and its comorbidities. Amor Belmeguenai is Associate Professor at the University Claude Bernard Lyon 1.

Jacques Bodennec, Co-founder

PhD, Expert in lipid biochemistry and physiology

Jacques research experience lies within biochemistry and physiology of complex lipids. He particularly specialized in the in vivo study of glycerophospholipids and sphingolipids metabolism and functions in normal and pathophysiological conditions. Jacques’s efforts are particularly devoted to the design and synthesis of lipids and derivatives of pharmaceutical interest. Jacques is associated Professor at the University Claude Bernard Lyon 1 and co-founder of a previous biotech company.

Leadership team